Categories Superactive High Afinity Leptin antagonist, mutein, multiple sclerosis, inflammatory bowel syndrome, rheumatoid arthritis, fibrosis, cardiovascular disease, CKD Cachexia, Osteoarthritis Development Stage (1) In vivo tests in ...

Background: Dental disorders occur when there are changes in oral hygiene, diet, medicaments or age. Our Innovation Novel dental coating that delivers therapeutics over time, as required, in response to sensed changes in acidic/basic conditions ...

  Background Many kinds of surfaces are notorious sources of infection. Eradication of bacteria immobilized as biofilms on these surfaces is a major biological problem. Prevention of the development of biofilms is of prime concern to ...

Once-daily, sustained-release Sirolimus delivery system Categories Oral Cavity, Oncology/Cancer, Sustained Release, Drug Delivery Development Stage Prototypes tested in vitro; pharmokinetic and pharmacodynamic testing in human volunteers ...

Background Metal based anti-tumor therapeutics Cisplatin and Carboplatin are two of the most widely prescribed anticancer agents. However, not all tumors can be treated with Cisplatin. In addition, Cisplatin may cause an extremely toxic ...

  Background With advances in biotechnology, nasal drug delivery is increasingly becoming a more viable alternative to oral and injectable routes of administration for an increasing number of drugs, including peptides. Our Innovation Platform ...

 Background Quorum sensing takes place in biofilms where microbes such as bacteria and fungi are at close proximity to one another Inter species quorum sensing may affect microbes’ physiology and virulence properties, resulting in the ...

Highlights Prevention of IgE-mediated allergic reaction by blocking and clearing pollen allergens with oxidized cellulose via its polysaccharide binding domain. Mode of administration: inhalation, intranasal, ocular, topical and ...

  Background DNA mutations in mitochondrial proteins/enzymes (nuclear encoded) that may lead to disease are present in approximately 1 in 8,000 individuals. Any treatment for mitochondrial diseases must be capable of targeting and crossing the ...